Overview

Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer

Status:
RECRUITING

Trial end date:
2028-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy(ADT) and standard salvage radiation therapy(SRT) or SRT combination with ADT in prostate cancer patients with biochemical recurrence of prostate-specific antigen(PSA) persistence after radical prostatectomy(RP).

Phase:

PHASE2

Details

Lead Sponsor:

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Treatments:

Androgen Antagonists